Visfatin is shown to significantly promote malignant progression of this cancer via activation of the insulin receptor (IR) and the phosphoinositide 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways. Here, INSR is linked to cancer.